Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Patients who added Cabometyx to Opdivo and Yervoy had a 27% lower risk of disease progression or death.
Can a person’s immune system help prevent two types of non-small-cell lung cancer? Here’s how Robert Keith, MD, hopes to find out.
About 1 in 1,000 pregnant women is diagnosed with cancer. Do newer treatments, such as immunotherapy, work in this group of patients?
“It is a really important development for our patients."
An intravenous infusion of two immunotherapy drugs, Opdualag blocks activity of the proteins LAG-3 and PD-1.
Neoadjuvant Opdivo plus chemotherapy improved outcomes for people with operable non-small-cell lung cancer.
Bill Evans, a melanoma survivor, turns his love of cycling into a community building and fundraising effort.
A combination of two immunotherapy drugs showed efficacy in the treatment of advanced melanoma in a phase 3 clinical trial.
A unique analysis measures treatment-free survival after immunotherapy in patients with advanced renal cell carcinoma.
Opdivo plus relatlimab delayed disease progression compared with Opdivo alone.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
In a small study, 80% of participants treated with Cabometyx and Opdivo underwent successful surgery.
People diagnosed with advanced melanoma may soon have a new treatment option that combines two immunotherapy drugs.
More people treated with Opdivo plus Yervoy reached the 6.5-year survival mark than those treated with either drug alone.
Checkpoint inhibitor doubled disease-free survival time after surgery.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.